Get the Daily Brief
Latest Biotech News
Takeda pays $1.2bn for Innovent oncology duo — global rights outside China
Takeda struck a $1.2 billion licensing and collaboration agreement with Innovent Biologics to acquire global rights (outside Greater China) to two late‑stage oncology candidates: IBI363, a...
Tango’s PRMT5 data satisfy — pivotal pancreatic study planned
Tango Therapeutics reported positive phase I/II results with vopimetostat (TNG‑462), a next‑generation MTA‑cooperative PRMT5 inhibitor, showing clinical activity in MTAP‑deleted pancreatic ductal...
Biogen licenses Vanqua's C5aR1 antagonist: $70M now, $990M possible
Biogen agreed to an exclusive worldwide license for Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million upfront and up to $990 million in milestones. Under the deal Biogen will lead...
FDA returns GSK’s Blenrep to market – approval limited to specific combos
The FDA granted a restricted approval for GSK’s antibody‑drug conjugate Blenrep, clearing it for use in combination with Velcade for patients whose multiple myeloma returned or progressed after at...
Lilly buys Adverum for gene therapy bet – cash rescue with CVR upside
Eli Lilly agreed to acquire cash‑strapped Adverum in a deal centered on ixo‑vec, the company’s phase‑3 intravitreal AAV gene therapy for wet age‑related macular degeneration. The transaction...
Inhibrx’s rare cancer win prompts BLA talk – regulators in view
Inhibrx reported registrational‑stage phase II results showing its monoclonal antibody ozekibart produced statistically significant and clinically meaningful progression‑free survival benefits in...
Tango’s PRMT5 data…pivotal path opens in pancreatic cancer
Tango Therapeutics released positive phase I/II data for vopimetostat (TNG‑462), a next‑generation PRMT5 inhibitor that leverages MTAP deletion cooperativity, showing encouraging activity in...
Takeda inks $1.2B oncology pact with Innovent — global rights outside China
Takeda signed a $1.2 billion licensing and collaboration agreement with China’s Innovent Biologics to obtain rights outside Greater China to two late‑stage oncology assets: IBI363, a...
AI accelerates antibiotic discovery: deep‑learning screens reveal new scaffolds
Two Nature Biotechnology reports demonstrate deep‑learning and virtual screening approaches that accelerate antibacterial discovery by surfacing structurally novel compounds from high‑throughput...
LNP shapes mapped: study links particle architecture to delivery performance
Researchers at the University of Pennsylvania, Brookhaven and industry partners published a detailed biophysical analysis of lipid nanoparticle (LNP) architectures, showing that LNPs adopt diverse...
Cellarity publishes cell‑state drug framework in Science — AI meets transcriptomics
Cellarity published a Science manuscript outlining a framework that integrates large transcriptomic datasets with AI modeling to identify compounds that correct pathological cell states. The...
10x, Roche and Prognosys sue Illumina — patent fights escalate in spatial and single‑cell
10x Genomics, joined by Roche Sequencing Solutions and licensor Prognosys, filed two federal lawsuits accusing Illumina of infringing on nine patents covering spatial biology and single‑cell...
Biogen bets $1B on Vanqua’s C5aR1 drug: upfront $70M, $990M in milestones
Biogen struck an exclusive global licensing deal for Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million up front with as much as $990 million in downstream payments. The agreement hands...
Lilly rescues Adverum: gene-therapy buy priced below market with CVR upside
Eli Lilly agreed to acquire cash-strapped Adverum in a deal that secures ixo-vec, an AAV-based intravitreal gene therapy in Phase 3 for wet age-related macular degeneration. The transaction values...
FDA clears new nonhormonal menopause drugs: elinzanetant and Bayer’s Lynkuet win approval
The FDA approved elinzanetant, a nonhormonal agent shown to reduce hot flashes and night sweats in clinical trials, and separately cleared Bayer’s Lynkuet as the first dual neurokinin-targeted...
Tango’s PRMT5 data clear path to pivotal study – $225M bridge financing follows
Tango Therapeutics reported phase I/II data for vopimetostat (TNG‑462), a next‑generation PRMT5 inhibitor engineered for MTAP‑deleted tumors, that the company said justify a planned pivotal study...
Inhibrx posts registrational win in rare chondrosarcoma – BLA plans underway
Inhibrx reported that its monoclonal antibody ozekibart hit the primary endpoint in a registrational phase II trial for advanced or metastatic unresectable chondrosarcoma, producing significant...
Deep learning hunts antibiotics: Nature Biotech papers deliver novel scaffolds
Two independent Nature Biotechnology reports demonstrated deep‑learning approaches that accelerate antibacterial discovery by prioritizing novel chemical scaffolds from high‑throughput and...
Retron editors resurface: metagenomic search yields new retron‑based gene editors
Researchers mined bacterial and archaeal metagenomes to identify retron elements that can be repurposed as self‑priming DNA editors compatible with CRISPR systems. The work validated candidate...
Personalized CRISPR in months: Baby KJ’s bespoke gene‑editing program shows the model
A rapid, multi‑partner effort produced a personalized CRISPR gene therapy for Baby KJ’s urea cycle disorder, converting academic discovery to a clinical candidate within months. The coordinated...